What should I do if I develop resistance to Fam-trastuzumab deruxtecan-nxki?

If drug resistance develops after taking Fam-trastuzumab deruxtecan-nxki, the patient should contact the doctor immediately. Since everyone has a different constitution and has different drug resistance responses, the doctor will be able to assess the condition and provide appropriate advice. Patients are not allowed to adjust the drug dosage on their own.

Trastuzumab contains a component, trastuzumab. Activation of downstream pathways such as PI3K/AK is a well-known resistance mechanism to trastuzumab, which is mainly related to PIK3CA mutations and PTEN deletion. If a patient develops resistance to trastuzumab, doctors may consider switching to other treatments or a combination of treatments. Sometimes, switching to a different drug or combination of drugs can provide better treatment results. In some cases, doctors may increase the dose or frequency of trastuzumab administration to enhance the effectiveness of the treatment. This requires careful evaluation by the physician of individual patient circumstances and tolerance. Doctors may also try other targeted therapies to find more effective treatment options, which may involve participating in clinical trials or using new targeted drugs.

Detrastuzumab is a new type of injectable anti-cancer drug. The original drug has been marketed in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear. The Hong Kong version of Detrastuzumab Specifications may cost more than 10,000 yuan per box of 100mg. The Hong Kong original version of Detrastuzumab may be more than RMB 10,000 per box. Tocilizumab Specifications of the original drugThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. There is currently no generic version of trastuzumab on the market. For more specific prices and drug information, please consult the medical consultant of the drug.